Ovary Tumor Markers And Methods Of Use Thereof

Abstract

Newly identified proteins as markers for the detection of ovary tumors, or as therapeutic targets for treatment thereof; affinity ligands capable of selectively interacting with the newly identified markers, methods for tumor diagnosis and therapy using the same.

1 .- 11 . (canceled) 
     
     
         12 . A method of treating a proliferative disease in a subject, the method comprising administering to the subject an antibody or a fragment thereof that specifically recognizes and binds to a KLRG2 protein. 
     
     
         13 . The method of  claim 12 , wherein the proliferative disease is an ovarian cancer. 
     
     
         14 . The method of  claim 12 , wherein the KLRG2 protein has an amino acid sequence that has at least 80% identity to SEQ ID NO: 85 or SEQ ID NO: 86. 
     
     
         15 . The method of  claim 12 , wherein the KLRG2 protein has an amino acid sequence that has at least 90% identity to SEQ ID NO: 85 or SEQ ID NO: 86. 
     
     
         16 . The method of  claim 12 , wherein the KLRG2 protein has an amino acid sequence that has at least 95% identity to SEQ ID NO: 85 or SEQ ID NO: 86. 
     
     
         17 . The method of  claim 12 , wherein the KLRG2 protein has an amino acid sequence selected from SEQ ID NO: 85 or SEQ ID NO: 86. 
     
     
         18 . The method of  claim 12 , wherein the antibody or fragment thereof modulates KLRG2 activity. 
     
     
         19 . The method of  claim 12 , wherein the antibody or fragment thereof inhibits or abolishes KLRG2 activity. 
     
     
         20 . The method of  claim 12 , wherein the antibody is a monoclonal antibody. 
     
     
         21 . The method of  claim 12 , wherein the antibody is a polyclonal antibody. 
     
     
         22 . The method of  claim 12 , wherein the antibody is labelled with a radioactive, fluorescent or enzyme label. 
     
     
         23 . The method of  claim 12  further comprising detecting the expression of KLRG2 protein in a tissue sample of the subject. 
     
     
         24 . The method of  claim 23 , wherein the tissue sample is an ovarian tissue sample. 
     
     
         25 . The method of  claim 23 , wherein the KLRG2 protein is detected by an immunoradiometric, immunoenzymatic or immunohistochemical assay. 
     
     
         26 . The method of  claim 12  further comprising detecting the expression of KLRG2 mRNA in a tissue sample of the subject. 
     
     
         27 . The method of  claim 26 , wherein the tissue sample is an ovarian tissue sample. 
     
     
         28 . The method of  claim 26 , wherein the KLRG2 mRNA is detected by polymerase chain reaction (PCR). 
     
     
         29 . The method of  claim 12 , wherein the subject is a human. 
     
     
         30 . A method of treating a proliferative disease in a subject, the method comprising administering to the subject a siRNA molecule that specifically silences KLRG2. 
     
     
         31 . The method of  claim 30 , wherein the proliferative disease is an ovarian cancer. 
     
     
         32 . The method of  claim 30 , wherein the siRNA molecule has a sequence complementary to SEQ ID NO: 87 or SEQ ID NO: 88. 
     
     
         33 . The method of  claim 29 , wherein the subject is a human.